Bluesky Facebook Reddit Email

B cells continue to work against SARS-CoV-2 months after infection, but do not recognize mutant

02.23.21 | American Association for the Advancement of Science (AAAS)

Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

A new analysis of B cells and more than 1,000 different monoclonal antibodies from 8 patients with COVID-19 shows that, contrary to previous hypotheses, protective B cell responses to the SARS-CoV-2 spike protein remain stable and continue to evolve over a 5-month period, many months after the initial period of active viral replication. However, a large proportion of the neutralizing antibodies generated from these long-lasting B cells did not efficiently recognize various emerging SARS-CoV-2 variants from Brazil and South Africa. These results - from an academia-industry collaboration - will help inform the design of future COVID-19 vaccines that work to constrain viral evolution and stimulate better neutralizing antibody and B cell responses against emerging SARS-CoV-2 variants. Mrunal Sakharkar and colleagues profiled spike protein-specific B cell and antibody responses in 8 patients with mild and severe COVID-19 over five months. Consistent with previous findings, they observed a significant decline in neutralizing antibody levels in the blood over time; however, levels of spike protein-specific memory B cells remained stable or even increased during the same time frame. As well, over the course of 120 days, monoclonal antibodies isolated from these B cells underwent increased somatic hypermutation, binding affinity, and neutralization potency - all signs of persistent B cell activity. The researchers also observed cross-neutralizing B cell populations, but these comprised just a small fraction of the B cell repertoire and were not prominent in the neutralizing response to SARS-CoV-2. Rather, a large proportion of the neutralizing antibody response only targeted conserved epitopes shared between SARS-CoV-2 and SARS-CoV and did not efficiently recognize emerging SARS-CoV-2 variants from Brazil and South Africa that harbor mutations at amino acid positions 417 and 484 of the spike protein. Thus, the authors suggest careful monitoring of circulating SARS-CoV-2 variants for variability in these protein sites to determine how these mutations impact vaccine-induced immunity.

###

Science Immunology

10.1126/sciimmunol.abg6916

Keywords

Article Information

Contact Information

SciPak Team
scipak@aaas.org

How to Cite This Article

APA:
American Association for the Advancement of Science (AAAS). (2021, February 23). B cells continue to work against SARS-CoV-2 months after infection, but do not recognize mutant. Brightsurf News. https://www.brightsurf.com/news/80EW9738/b-cells-continue-to-work-against-sars-cov-2-months-after-infection-but-do-not-recognize-mutant.html
MLA:
"B cells continue to work against SARS-CoV-2 months after infection, but do not recognize mutant." Brightsurf News, Feb. 23 2021, https://www.brightsurf.com/news/80EW9738/b-cells-continue-to-work-against-sars-cov-2-months-after-infection-but-do-not-recognize-mutant.html.